{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:43:20Z","timestamp":1760985800956,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00120","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T04:43:26Z","timestamp":1550465006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives"],"prefix":"10.3389","volume":"10","author":[{"given":"Lloyd","family":"Tanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.","volume":"307","author":"Andries","year":"2005","journal-title":"Science."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1086\/428051","article-title":"The quinolones: past, present, and future.","volume":"41","author":"Andriole","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.bmcl.2016.05.024","article-title":"Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.","volume":"26","author":"Beteck","year":"2016","journal-title":"Bioorganic. Med. Chem. Lett."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-018-0062-7","article-title":"Accessible and distinct decoquinate derivatives active against Mycobacterium tuberculosis and apicomplexan parasites.","volume":"1","author":"Beteck","year":"2018","journal-title":"Commun. Chem."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01627","article-title":"The mycobacterial membrane: a novel target space for anti-tubercular drugs.","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1016\/j.bmcl.2013.07.006","article-title":"A medicinal chemists\u2019 guide to lead optimization for tuberculosis.","volume":"23","author":"Dartois","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yrtph.2013.07.005","article-title":"Opinion of the scientific panel on additives and products or substances used in animal feed on a request from the commission on the coccidiostat DECCOX in accordance with article 9G of council directive 70\/524\/EEC.","volume":"17","year":"2003","journal-title":"EFSA J."},{"journal-title":"Guidance for Industry Bioanalytical Method Validation Guidance for Industry Bioanalytical Method Validation.","year":"2018","key":"B11"},{"key":"B12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tube.2012.07.003","article-title":"Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.","volume":"92","author":"Franzblau","year":"2012","journal-title":"Tuberculosis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1128\/AAC.26.1.94","article-title":"In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.","volume":"26","author":"Gay","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance.","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"B16","first-page":"51","article-title":"\u201cMycobacteria: II chemotherapy,\u201d in","author":"Grosset","year":"1998","journal-title":"Experimental Chemotherapy of Mycobacterial Diseases BT"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2474","article-title":"Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.","volume":"9","author":"Hurdle","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.","volume":"48","author":"Jayaram","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice.","volume":"148","author":"Ji","year":"1993","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jpba.2005.12.020","article-title":"Prediction of the permeability of drugs through study on quantitative structure\u2013permeability relationship.","volume":"41","author":"Jung","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1128\/AAC.01567-12","article-title":"A physiologically based pharmacokinetic model of rifampin in mice.","volume":"57","author":"Lyons","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cmdc.201700579","article-title":"Preliminary evaluation of artemisinin\u2013cholesterol conjugates as potential drugs for the treatment of intractable forms of malaria and tuberculosis.","volume":"13","author":"Morake","year":"2018","journal-title":"ChemMedChem"},{"key":"B24","first-page":"1316","article-title":"Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.","volume":"29","author":"Naritomi","year":"2001","journal-title":"Drug Metab. Dispos."},{"journal-title":"Guide for the Care and use of Laboratory Animals","year":"2011","key":"B25"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1128\/AAC.02041-15","article-title":"Towards an evidence-based non-clinical roadmap for evaluating the efficacy of new TB drug regimens: proceedings of a critical path to tb drug regimens (CPTR)-national institute of allergy and infectious disease (NIAID) in vivo pharmacology workshop for Tu.","volume":"60","author":"Nuermberger","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1124\/dmd.30.7.831","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes.","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"B28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jac\/47.4.447","article-title":"Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.","volume":"47","author":"Onodera","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","first-page":"435","article-title":"Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs.","volume":"291","author":"Palm","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/AAC.00720-11","article-title":"Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.","volume":"56","author":"Rouan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jac\/43.suppl_2.61","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats.","volume":"43","author":"Siefert","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5702\/massspectrometry.A0025","article-title":"Quantification of small molecule drugs in biological tissue sections by imaging mass spectrometry using surrogate tissue-based calibration standards.","volume":"3","author":"Takai","year":"2014","journal-title":"Mass Spectrom."},{"key":"B34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2885.2012.01421.x","article-title":"The history of decoquinate in the control of coccidial infections in ruminants.","volume":"35","author":"Taylor","year":"2012","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/769234","article-title":"Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity.","volume":"2013","author":"Wang","year":"2013","journal-title":"Malar. Res. Treat."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1056\/NEJMe1410977","article-title":"Shortening treatment for tuberculosis \u2014 back to basics.","volume":"371","author":"Warner","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1021\/jm001020e","article-title":"High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes.","volume":"44","author":"Wohnsland","year":"2001","journal-title":"J. Med. Chem."},{"journal-title":"Global Tuberculosis Programme. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update.","year":"2016","key":"B38"},{"journal-title":"Global Tuberculosis Report 2018.","first-page":"1","year":"2018","key":"B39"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-10","article-title":"Multidrug-resistant tuberculosis.","volume":"8","author":"Zager","year":"2008","journal-title":"BMC Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T04:43:28Z","timestamp":1550465008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":40,"alternative-id":["10.3389\/fphar.2019.00120"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00120","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"article-number":"120"}}